Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marimastat in SCLC Patients Responding to First-Line Chemotherapy
NCT00003011Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 1997
- Primary completion
- Feb 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Marimastat with Placebo (2 arms). Primary endpoint: Overall Survival at 4 years. Started Jan 1997; status: completed.
02
Drugs
marimastat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003011.